Where positive symptoms develop, the duration of untreated psychosis (DUP) is emerging as a predictor of future disability and illness course, particularly when it exceeds 1 year. Specifically, Loebel found that, rather than premorbid adjustment, age of onset, mode of onset, or illness severity, DUP best predicted the time to treatment response (3) . The Northwick Park Study showed that DUP of less than 1 year was a stronger predictor of avoiding relapse at 2 years than was maintenance-medication status (4) . Loebel postulated that active psychosis may represent the expression of a toxic neurobiological process, with each subsequent relapse rendering the patient more susceptible to another (5) . For these reasons, early detection and prevention, or early treatment of relapse, are crucial foci of services. The etiology of delayed initial treatment is complex; it includes factors related to the mode and rapidity of illness onset, patient factors related to help seeking and the social support network, and systems issues relevant to the ease of service access (6) . Therefore, any attempts to reduce the DUP must come from a multilayered approach; a broad educational focus is needed to reduce treatment delay and to ensure prompt, effective treatment from EI teams once psychosis is detected.
Eaton and others showed that many measures of symptomatology and psychosocial outcome taken 2 years after treatment of the initial psychotic episode are little different from those taken many years later (7) . This suggests that after a "critical period" (8) early in the illness course, the sustained level of general disability does not change. This implication is double-edged: it provides further evidence against the progressive deterioration described by Kraepelin, but it also suggests that for many patients the expectations of functional or symptomatic recovery are limited after a certain period of being unwell. We propose that assertive attempts to reduce symptoms and restore social and vocational status during this period may have disproportionately beneficial long-term effects, although clear evidence for this does not yet exist.
Current research increasingly supports such clinical targets as preventing movement from the prodromal phase to acute psychosis, reducing the length of unresolved psychosis, and implementing assertive psychosocial interventions in the recovery period. Further longer-term prospective studies with data regarding illness course in treatment, as well as cost, will add to current knowledge.
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D 2 Antagonist Augmentation in Patients With a Partial Response to Atypical Antipsychotics
Dear Editor:
Atypical antipsychotic medications have become the first-line treatment for schizophrenia (1) because of their broader efficacy and lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) (2). Clozapine is indicated in treatment-resistant schizophrenia (3); however, for patients who cannot tolerate clozapine therapy or who reveal only partial response to it (4), targeted treatment strategies tailored to the variable expression of schizophrenia in each patient are in order (5) . Coprescribing typical, atypical, and depot antipsychotic agents may be considered (6) .
We report 4 cases of individuals who met DSM-IV criteria for schizophrenia that only partially responded to monotherapy. For 12 weeks, a classic antipsychotic agent was added to ongoing atypical drug therapy on an open-label basis. Results were assessed with the Clinical Global Impression (CGI) scale .
Case Report 1
A woman aged 29 years, who had been diagnosed at age 16 years with unspecified schizophrenia, had a baseline CGI score of 6. Olanzapine was initiated at 20 mg daily, and anxiety and troubling ideas of reference ameliorated (CGI score, 5). After 6 weeks, zuclopenthixol was added and titrated to 60 mg daily. The patient's ideas of reference disappeared and anxiety diminished (CGI score, 4).
Case Report 2
A man aged 23 years, who had been diagnosed at age 17 years with severe disorganized schizophrenia (CGI score, 7), had disorganized speech and behaviour that did not respond to typical antipsychotics. Olanzapine 20 mg daily yielded only a minor improvement. Clozapine 250 mg daily was initiated, and the patient showed remarkable improvement (CGI score, 5). Three months later, clotiapine 80 mg daily was added, and further progress was noted (CGI score, 4).
Case Report 3
A woman aged 40 years, with severe paranoid schizophrenia onset at age 24 years, was socially isolated following her last psychotic episode (CGI score, 7). Olanzapine 20 mg daily diminished her paranoid ideation (CGI score, 5). Three months later, her treatment regimen was augmented with haloperidol 15 mg daily.
Her functioning further improved, and paranoid ideation ceased (CGI score, 4).
Case Report 4
A man aged 52 years had chronic, unremitting, paranoid schizophrenia beginning at age 24 years. He was hospitalized following severe paranoid delusions (CGI score, 7).Treatment with olanzapine 20 mg daily yielded mild improvement (CGI score, 6). Six weeks later, perphenazine was added and titrated to 16 mg daily. His paranoid delusions gradually lost their disabling nature and improvement was noted (CGI score, 5).
Discussion
Medical management of treatmentrefractory psychosis patients poses a difficult challenge. Although widespread use of atypical antipsychotic agents has improved patient outcomes, some patients still do not respond to treatment. The Texas Medication Algorithm Project (7) suggested a combination of typical and atypical medications for partial responders. The rationale lies in their different mechanisms of action: dopamine and postsynaptic 5-HT 2A blockade. Combined therapy has been described in case reports, but randomized trials are lacking (8) (9) In our 4 chronic schizophrenia patients, combined typical and atypical antipsychotic therapy led to marked improvement. We chose adjuvant classic antipsychotic agents according to each individual patient's prior side effect profile.
Though remission was not achieved, the polypharmacy reduced side effects and enabled their discharge to day care. This treatment alternative provides an additional option in the ongoing struggle to treat patients with refractory schizophrenia.
